Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway

Journal of Infectious Diseases

Volumn 211, Issue 2, 2015, Pages 206-215

  Burger, Emily A ^a,c   Sy, Stephen ^c   Nygard, Mari ^b   Kristiansen, Ivar S ^a   Kim, Jane J ^c  

^a UNIVERSITY OF OSLO   (Norway)

^b CANCER REGISTRY OF NORWAY   (Norway)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

cost effectiveness analysis; disease transmission models; herd immunity; human papillomavirus; vaccine

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGE DISTRIBUTION; ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; DRUG COST; FEMALE; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; NORWAY; PAPILLOMAVIRUS INFECTION; THERAPY DELAY; TREATMENT OUTCOME; VACCINATION; ADOLESCENT; CHILD; ECONOMICS; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; NORWAY; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; YOUNG ADULT;

EID: 84922431385     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu413     Document Type: Article

References (37)

1. zur Hausen H. Papillomaviruses in the causation of human cancers-A brief historical account. Virology 2009; 384:260-5.
2. Lacey CJN, Lowndes CM, Shah KV. Burden and management of noncancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24:35-41.
3. Markowitz LE, Tsu V, Deeks SL, et al. Human papillomavirus vaccine introduction-The first five years. Vaccine 2012; 30:F139-48.
4. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30: F123-38.
5. Castellsague X, Munoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011; 105:28-37.
6. Turner HC, Baussano I, Garnett GP. Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine. PLoS One 2013; 8:e75552.
7. Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women. J Natl Cancer Inst 2014; 106:djt460.
8. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013; 346:f2032.
9. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013; 208:385-93.
10. Norwegian Directorate of Health. Economic evaluation of healthcare-A guide. Oslo, Norway: Norwegian Directorate of Health, 2012.
11. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359:821-32.
12. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009; 339:b3884.
13. Burger E, Sy S, Nygår M, Kristiansen I, Kim J. Prevention of HPVrelated cancers in Norway: Cost-effectiveness of expanding the HPV vaccination programme to include pre-Adolescent boys. PLoS One 2014; 9:e89974.
14. Kim JJ, Kuntz KM, Stout NK, et al. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007; 166:137-50.
15. Burger EA, Ortendahl JD, Sy S, Kristiansen IS, Kim JJ. Costeffectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br J Cancer 2012; 106:1571-8.
16. Goldhaber-Fiebert JD, Stout NK, Ortendahl J, Kuntz KM, Goldie SJ, Salomon JA. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr 2007; 5:11.
17. Cancer Registry of Norway. Institute of Population-Based Cancer Research. http://www.kreftregisteret.no. Accessed 1 February 2013.
18. Villa LL, Perez G, Kjaer SK, et al. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007; 196:1438-46.
19. Federal Reserve. Historical rates for the Norwegian Krone, 2011. http://www.federalreserve.gov/RELEASES/H10/Hist/dat00-no.htm. Accessed 13 June 2011.
20. Conway EL, Farmer KC, Lynch WJ, Rees GL, Wain G, Adams J. Quality of life valuations of HPV-Associated cancer health states by the general population. Sex Transm Infect 2012; 88:517-21.
21. Woodhall SC, Jit M, Soldan K, et al. The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK. Sex Transm Infect 2011; 87:458-63.
22. Cancer Registry of Norway. 2008 annual report population-based screening against cervical cancer. Oslo: Cancer Registry of Norway, 2009.
23. Jimenez E, Wisløff T, Klemp M. Cost-effectiveness of a HPVvaccination catch-up program for females aged 26 years or younger in a Norwegian setting. Report from Kunnskapssenteret no. 5-2014. Oslo: Norwegian Knowledge Centre for the Health Services, 2014.
24. Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine 2012; 30:F157-67.
25. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337:a769.
26. Dasbach EJ, Insinga RP, Elbasha EH. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. Bjog-An Int J Obstet Gynaecol 2008; 115:947-56.
27. Olsen J, Jepsen MR. Human papillomavirus transmission and costeffectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care 2010; 26:183-91.
28. Elbasha EH, Dasbach EJ, Insinga RP, Haupt RM, Barr E. Age-based programs for vaccination against HPV. Value Health 2009; 12:697-707.
29. Usher C, Tilson L, Olsen J, Jepsen M, Walsh C, Barry M. Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine 2008; 26:5654-61.
30. Statens SerumInstitute. EPI-NEWS. http://www.ssi.dk/English/News/EPINEWS/2013/No%2020%20-%202013.aspx. Accessed 20 December 2013.
31. Australian Government Department of Health. Immunise human papillomavirus (HPV). http://www.health.gov.au/internet/immunise/publishing.nsf/content/immunise-hpv. Accessed 20 December 2013.
32. Malagón T, Drolet M, Boily M, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-Analysis. Lancet Infect Dis 2012; 12:781-9.
33. Leval A, Herweijer E, Ploner A, et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst 2013; 105:469-74.
34. Health Protection Agency. Number & rates of anogenital warts diagnosed in England, 2002-2011. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/1296688631209. Accessed 11 January 2013.
35. Omland T, Akre H, Vardal M, Brondbo K. Epidemiological aspects of recurrent respiratory papillomatosis: A population-based study. Laryngoscope 2012; 122:1595-9.
36. World Health Organization. ICO (Institut Català d'Oncologia). Information Centre on Human Papilloma Virus (HPV) and Cervical Cancer: data query system. http://www.who.int/hpvcentre/en/. Accessed 15 November 2012.
37. Mork J. Prevalence of HPV in oropharyngeal carcinomas in patients diagnosed at Oslo University Hospital 2010-1011 [conference proceeding]. Presented at: MD Anderson GAP Conference, 2012. http://webtv. medinfo.no/Mediasite/Play/99a9cb5b7412477c8a92e0413 db5321b1d? catalog=54190625-deb6-433e-869c-b4fbf3b58b6c. Accessed 2 February 2013.